As an emerging therapy in the market, BNCT has received attention from more and more medical institutions across the globe with its low cost, high response rate, short treatment time and non-intrusive features.

The research bottleneck remained until Dr. GP Yeh, an American born Chinese expert in high-energy physics, developed the accelerator technology for producing adequate number of neutrons by building on the proton technology in the National Fermi Accelerator Laboratory (FERMILAB) in the United States, which marked a major stride in the development of BNCT.

Based on the German National Innovation Model and ecosystem network investment strategy as the core investment philosophy, we have launched the SP to realize the value investments in the BNCT industry.

To accomplish the abovementioned investment objectives, we comply with the regulations of relevant supervisory authorities by setting up a fund offering and management framework in compliance with Economic Substance Act, international anti-money laundering regulations and fund governance standards for safeguarding the interests of fund investors and building the bridge between market capital and development of BCNT industry to realize the goal of industrialization and strive for a higher return for the investors.

The total size of this fund is 200 million US dollars and the first fundraising to reach an amount of 80 million US dollars is under way.

• For investors, BNCT will be new technology which has a profound on the development of medication. The advent of BNCT, however, does not entail abandonment of all other cancer therapies. In fact, BNCT can be coupled with other treatments to provide the patients with better medication quality and increase the response rate.


• As compared with other major traditional cancer treating methods, immunotherapy and radioactive therapy, the advantages of BNCT are manifest in the three aspects：